ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX) from its SEC filings: 2025 revenue $113.3 million (+668% vs the year before), net margin -310%, free cash flow -$308.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $113.3 million |
| Revenue growth | +668% |
| Net income | -$351.5 million |
| Net margin | -310.3% |
| Free cash flow | -$308.8 million |
| Diluted EPS | $-0.38 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +94% |
| Cash | $75.7 million |
| Share count, 1 year | +12% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.